The difficulty of securing capital for life science development companies in recent years has hardly gone unnoticed. The question is whether this financial permafrost is the result of a series of unfortunate, interacting circumstances, or whether it is a natural development in an industry where the willingness to pay for incremental improvements is weakening?
Anna Törner: ”Drug prices – an important driver of innovation”
We live under the illusion that no price is too high when it comes to health, but that simply isn’t true, writes Anna Törner.
Advertisement
BREAKING